{
    "organizations": [],
    "uuid": "c34cee16557cb2d5f65b364c3f3dbdad85db9520",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-prometics-pbi-4050-phase-3-pivotal/brief-prometics-pbi-4050-phase-3-pivotal-clinical-trial-design-for-idiopathic-pulmonary-fibrosis-finalized-idUSASB0C2OJ",
    "ord_in_thread": 0,
    "title": "BRIEF-Prometic's Pbi-4050 Phase 3 Pivotal Clinical Trial Design For Idiopathic Pulmonary Fibrosis Finalized",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 29 (Reuters) - Prometic Life Sciences Inc:\n* PROMETIC‘S PBI-4050: PHASE 3 PIVOTAL CLINICAL TRIAL DESIGN FOR IDIOPATHIC PULMONARY FIBROSIS (IPF) FINALIZED\n* PROMETIC LIFE SCIENCES - BASED ON RECOMMENDATIONS FROM FDA, CO NOW WILL UNDERTAKE AN “ALL COMERS STUDY”\n* PROMETIC - PBI-4050 STUDY WILL ENROLL PATIENTS WITH MILD-TO-MODERATE IPF, REGARDLESS OF BACKGROUND STANDARD OF CARE WITH NINTEDANIB OR NOT Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-29T20:06:00.000+02:00",
    "crawled": "2018-01-30T19:13:39.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "prometic",
        "life",
        "science",
        "inc",
        "prometic",
        "phase",
        "pivotal",
        "clinical",
        "trial",
        "design",
        "idiopathic",
        "pulmonary",
        "fibrosis",
        "ipf",
        "finalized",
        "prometic",
        "life",
        "science",
        "based",
        "recommendation",
        "fda",
        "co",
        "undertake",
        "comer",
        "study",
        "prometic",
        "study",
        "enroll",
        "patient",
        "ipf",
        "regardless",
        "background",
        "standard",
        "care",
        "nintedanib",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}